Skip to main content

Research Repository

Advanced Search

All Outputs (3)

All Surfaces Are Not Equal in Contact Transmission of SARS-CoV-2 (2020)
Journal Article
Xue, X., Ball, J. K., Alexander, C., & Alexander, M. R. (2020). All Surfaces Are Not Equal in Contact Transmission of SARS-CoV-2. Matter, 3(5), 1433-1441. https://doi.org/10.1016/j.matt.2020.10.006

© 2020 Elsevier Inc. The world faces a severe and acute public health emergency due to the ongoing coronavirus disease 2019 (COVID-19) global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Healthcare workers are... Read More about All Surfaces Are Not Equal in Contact Transmission of SARS-CoV-2.

Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV (2020)
Journal Article
Mosa, A. I., AbouHaidar, M. G., Urbanowicz, R. A., Tavis, J. E., Ball, J. K., & Feld, J. J. (2020). Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV. Virology Journal, 17, Article 140. https://doi.org/10.1186/s12985-020-01408-9

Despite available treatments, a prophylactic HCV vaccine is needed to achieve elimination targets. HCV vaccine development has faltered largely because the extreme diversity of the virus limits the protective breadth of vaccine elicited antibodies. I... Read More about Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV.

A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice (2020)
Journal Article
Mosa, A. I., Urbanowicz, R. A., AbouHaidar, M. G., Tavis, J. E., Ball, J. K., & Feld, J. J. (2020). A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice. Vaccine, 38(44), 6864-6867. https://doi.org/10.1016/j.vaccine.2020.08.066

© 2020 Elsevier Ltd Vaccine development for antigenically variable pathogens has faltered because extreme genetic diversity precludes induction of broadly neutralizing antibodies (nAB) with classical vaccines. Here, using the most variable epitope of... Read More about A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice.